Form 4: Iovance Biotherapeutics CFO Reports Stock Transactions
SEC Form 4 Filing
Jean-Marc Bellemin, CFO of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On March 3, 2025, Jean-Marc Bellemin, the Chief Financial Officer of Iovance Biotherapeutics, had 58,590 restricted stock units (RSUs) vest.
- The company withheld 31,734 shares to satisfy tax obligations at a price of $4.04 per share.
- Following these transactions, Bellemin directly owns 56,204 shares of common stock and 70,317 RSUs.
- The remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing reflecting standard executive compensation practices, and doesn't inherently indicate positive or negative sentiment.
Future Outlook
The remaining RSUs will vest in equal quarterly installments.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding insider transactions.
Stakeholder Impact
- The vesting of RSUs and subsequent tax withholding has a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of grant for the RSUs held by the Reporting Person. |
| 03/03/2025 | Date of RSU vesting and tax withholding. |
| 03/05/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.